Ex Vivo TU Conversion and Oral TRT Dosing Accuracy

Ex vivo conversion of TU to testosterone can inflate lab values after a blood draw, risking dosing errors. With 3–6 hour timing and validated plain tubes, clinics can monitor oral TRT accurately without special supplies.

Estimated reading time: 10 minutes

Key takeaways

Ex vivo conversion of testosterone undecanoate (TU) to testosterone (T) after the blood draw can inflate measured T and mislead dosing decisions if not controlled.
FDA concerns were resolved with tube/processing validation, PK modeling, and a small adjustment factor enabling accurate monitoring without special collection supplies.
A single 3–6 hour post-dose sample (commonly 4–6 hours) using validated plain tubes reliably reflects average exposure for Jatenzo and Tlando titration.
NaF/EDTA tubes suppress ex vivo conversion but may under-report T at higher TU levels; labels rely on validated plain-tube methods instead.

Why Oral TRT Monitoring Got Complicated
What the FDA Required—and How It Was Resolved
What the Studies Actually Found
Practical Implications for Oral TRT Monitoring
Safety Context: What Else Gets Monitored
Limitations and Open Questions
Considerations for Clinics and Laboratories
What This Means for Patients on Jatenzo or Tlando
How Taurus Meds Approaches Oral TRT Monitoring
Conclusion
Disclaimer
Sources

Why Oral TRT Monitoring Got Complicated

Oral testosterone undecanoate (TU) products like Jatenzo and Tlando have made testosterone replacement therapy (TRT) more convenient for many men. But they also introduced a technical challenge for labs and clinicians: blood draws can overestimate testosterone if TU in the sample converts to testosterone (T) after the draw. The FDA scrutinized this issue for years. The good news: tube and processing validation now support reliable oral TRT monitoring using a single timed blood draw—without exotic collection supplies—when conducted according to product labeling and validated methods.

This section explains what changed, why it matters for accuracy, and what patients and clinics should understand about timing, tube type, and interpretation.

Mechanism: Plasma and serum contain esterases that can cleave TU into T after collection. If this happens in the tube, the assay “sees” more T than was in circulation at draw time.
Clinical consequence: Overestimation of serum T can prompt down-titration or maintenance of a subtherapeutic dose.
Concentration dependence: Ex vivo conversion is more pronounced when post-dose TU is higher, making timed draws sensitive to handling.

What the FDA Required—and How It Was Resolved

Tlando’s multi-year review history illustrates the issue and its resolution. Between 2016 and 2019, the FDA issued Complete Response letters for Tlando, citing an inability to exclude clinically relevant ex vivo conversion as a source of bias in measured testosterone. This was not about efficacy; it was about ensuring routine lab methods could guide dosing accurately.

Two strands of evidence resolved the concern:

Tube and processing validation
- Ex vivo TU-to-T conversion is concentration-dependent.
- NaF (±EDTA) tubes reduced conversion by roughly 30–85% versus plain tubes.
- At higher TU levels (e.g., >15 ng/mL), NaF tubes produced ~14–30% lower measured T, suggesting under-reporting at clinically relevant concentrations.
- Cold processing (~4°C) minimized ex vivo conversion across tube types.
PK modeling, simulations, and a small adjustment factor
- For Jatenzo and Tlando, modeling linked a single timed post-dose T value to 24-hour average exposure (Cavg), the efficacy anchor.
- The strongest window was 3–6 hours post-dose (often ~4 hours), with ~88–95% concordance with Cavg.
- A small validated correction (about 3% in some analyses; up to ~3–8% for parameters like Cmax) aligned plain-tube measurements with true exposure.

This evidence enabled Jatenzo’s approval (2019) and Tlando’s subsequent approvals. Plain tubes with validated timing/processing—and a small adjustment—met the FDA’s practicality and accuracy bar.

What the Studies Actually Found

Ex vivo conversion is real but manageable. Cooling and timely separation mitigate the effect, which is larger when TU is high.
NaF/EDTA tubes reduce conversion but may under-report T when TU concentrations are higher, complicating universal use.
Modeling supports a single timed sample. A 3–6 hour post-dose draw correlates well with Cavg for eugonadal targeting.
High concordance with Cavg. Analyses for Jatenzo and Tlando reported ~88–95% agreement using the validated timing and plain-tube approach.
Phase 3 outcomes aligned. Tlando’s fixed-dose regimen and Jatenzo’s titratable regimen met efficacy targets using these methods.

Caution: Inter-site variability may occur; a site with irregular handling produced outlier Cmax values in one FDA review—underscoring the importance of consistent timing and processing.

Practical Implications for Oral TRT Monitoring

A single, timed post-dose sample works. Labels rely on a 3–6 hour post-dose draw (commonly 4–6 hours) to gauge average exposure.
Plain tubes are acceptable when used as validated. No exotic tubes are required in routine practice when handling follows validated methods.
Why not always use NaF/EDTA? They lessen conversion but can under-report T at higher TU levels; labeling reflects a practical, validated plain-tube approach with a small correction.
Timing matters. Drawing too early or too late can misrepresent exposure; the 3–6 hour window is PK-driven.
Interpretation guides titration. Clinicians use the timed T value to adjust within approved ranges, aiming for eugonadal exposure while monitoring safety labs.

Safety Context: What Else Gets Monitored

Blood pressure: Oral TU products carry a boxed warning for BP increases (often ~3–5 mmHg). Baseline CV risk assessment and on-therapy monitoring are standard.
Hematologic changes: Average hematocrit increases (e.g., ~3.2%) occur with TRT. Baseline and periodic checks are recommended.
Contraindications and precautions: As with all TRT, observe label-directed warnings (e.g., prostate/breast cancer considerations) and routine safety monitoring.

Limitations and Open Questions

Universal adjustment factor: The exact correction may vary across doses, populations, and lab platforms.
Real-world performance: Community variability in timing, handling, and assays can influence accuracy.
High TU concentrations: The NaF vs. plain-tube differences at very high TU levels warrant ongoing attention.
Populations studied: Precision data often come from Phase 1/3 hypogonadal male cohorts; broader generalizability is inferred.

Considerations for Clinics and Laboratories

Align the draw with dosing: Schedule testosterone measurement 3–6 hours post-dose per product labeling.
Use validated plain tubes: These underpinned efficacy/safety decisions and are practical with proper handling.
Emphasize prompt, controlled processing: Cooling and timely separation reduce ex vivo conversion variability.
Be alert to outliers: Unexpected values, or deviations in timing/handling, may merit repeat testing.

Consistency in timing and handling—more than tube type alone—drives reliable results.

What This Means for Patients on Jatenzo or Tlando

Expect a timed blood draw: Typically a few hours after your dose (not before dosing), unlike some injection/gel protocols.
Standard labs are usually fine: Routine supplies and validated plain tubes are typically sufficient.
Share details with your lab: Confirm product name and timing so staff coordinate the post-dose window correctly.
Stay current on safety labs: Blood pressure checks and periodic hematologic labs remain part of care.

How Taurus Meds Approaches Oral TRT Monitoring

We coordinate with labs that understand the 3–6 hour post-dose timing used in labeling.
We interpret results alongside symptoms, safety parameters, and consistent lab methods.
We titrate within approved strategies to maintain eugonadal exposure while prioritizing safety and practicality.

Our goal: predictable, reproducible monitoring—so dose decisions reflect physiology, not collection artifacts.

Conclusion

Ex vivo conversion of TU to testosterone in blood samples was a legitimate hurdle for oral TRT monitoring. Through multiple FDA review cycles, manufacturers demonstrated that a single, timed post-dose sample collected in plain tubes—paired with validated handling and a small adjustment—accurately reflects average testosterone exposure for Jatenzo and Tlando. This enables practical, clinic-friendly monitoring without sacrificing reliability.

Open questions persist around universal adjustments and real-world workflow variability, but the core message is encouraging: with attention to timing and consistent processing, oral TRT can be monitored accurately enough to guide dosing decisions, while maintaining regular safety surveillance for blood pressure and hematologic effects.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalized recommendations on TRT monitoring and dosing.